In vitro efficacy of Artemisia extracts against SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Background
Traditional medicines based on herbal extracts have been proposed as affordable treatments for patients suffering from coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Teas and drinks containing extracts of Artemisia annua and Artemisia afra have been widely used in Africa in efforts to prevent SARS-CoV-2 infection and fight COVID-19.
Methods
The plant extracts and Covid-Organics drink produced in Madagascar were tested for plaque reduction using both feline coronavirus and SARS-CoV-2 in vitro. Their cytotoxicities were also investigated.
Results
Several extracts as well as Covid-Organics inhibited SARS-CoV-2 and FCoV infection at concentrations that did not affect cell viability.
Conclusions
Some plant extracts show inhibitory activity against FCoV and SARS-CoV-2. However, it remains unclear whether peak plasma concentrations in humans can reach levels needed to inhibit viral infection following consumption of teas or Covid-Organics. Clinical studies are required to evaluate the utility of these drinks for COVID-19 prevention or treatment of patients.
Article activity feed
-
-
SciScore for 10.1101/2021.02.14.431122: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Plaques of FCoV were stained with specific antibodies (primary antibody: mouse anti feline coronavirus monoclonal antibody at 1:500 dilution solution, Bio-Rad; secondary antibody: Alexa 488-labeled goat anti-mouse at a 1:500 dilution; Thermo Fisher) and counted manually by fluorescence microscopy (Axio observer, Zeiss). anti feline coronavirussuggested: (Acris Antibodies GmbH Cat# SM1870P, RRID:AB_981215)anti-mousesuggested: None… SciScore for 10.1101/2021.02.14.431122: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Plaques of FCoV were stained with specific antibodies (primary antibody: mouse anti feline coronavirus monoclonal antibody at 1:500 dilution solution, Bio-Rad; secondary antibody: Alexa 488-labeled goat anti-mouse at a 1:500 dilution; Thermo Fisher) and counted manually by fluorescence microscopy (Axio observer, Zeiss). anti feline coronavirussuggested: (Acris Antibodies GmbH Cat# SM1870P, RRID:AB_981215)anti-mousesuggested: NoneExperimental Models: Cell Lines Sentences Resources VeroE6 cells were seeded at 10,000 cells per well of flat bottom 96-well plates (Thermo Fisher Scientific, Roskilde VeroE6suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Software and Algorithms Sentences Resources Covid-Organics was purchased in Madagascar. Madagascarsuggested: (Madagascar, RRID:SCR_003274)Sigmoidal dose response curves were fitted and median cytotoxic concentration (CC50) values were calculated with GraphPad Prism 8.0.0. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-